MX389966B - Combinaciones de cabozantinib y atezolizumab para tratar cancer. - Google Patents

Combinaciones de cabozantinib y atezolizumab para tratar cancer.

Info

Publication number
MX389966B
MX389966B MX2019008032A MX2019008032A MX389966B MX 389966 B MX389966 B MX 389966B MX 2019008032 A MX2019008032 A MX 2019008032A MX 2019008032 A MX2019008032 A MX 2019008032A MX 389966 B MX389966 B MX 389966B
Authority
MX
Mexico
Prior art keywords
cabozantinib
atezolizumab
cancer
combinations
treatment
Prior art date
Application number
MX2019008032A
Other languages
English (en)
Other versions
MX2019008032A (es
Inventor
Christian Scheffold
Colin Hessel
Gisela Schwab
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61569414&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX389966(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of MX2019008032A publication Critical patent/MX2019008032A/es
Publication of MX389966B publication Critical patent/MX389966B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Esta invención se refiere a la combinación de cabozantinib y atezolizumab para tratar tumores sólidos metastásicos o localmente avanzados, particularmente, carcinoma de células renales o cáncer urotelial avanzado.
MX2019008032A 2017-01-20 2018-01-19 Combinaciones de cabozantinib y atezolizumab para tratar cancer. MX389966B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762448869P 2017-01-20 2017-01-20
US201762458447P 2017-02-13 2017-02-13
PCT/US2018/014523 WO2018136796A1 (en) 2017-01-20 2018-01-19 Combinations of cabozantinib and atezolizumab to treat cancer

Publications (2)

Publication Number Publication Date
MX2019008032A MX2019008032A (es) 2019-12-16
MX389966B true MX389966B (es) 2025-03-20

Family

ID=61569414

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019008032A MX389966B (es) 2017-01-20 2018-01-19 Combinaciones de cabozantinib y atezolizumab para tratar cancer.
MX2022001718A MX2022001718A (es) 2017-01-20 2019-07-03 Combinaciones de cabozantinib y atezolizumab para tratar cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022001718A MX2022001718A (es) 2017-01-20 2019-07-03 Combinaciones de cabozantinib y atezolizumab para tratar cancer.

Country Status (15)

Country Link
US (2) US11198731B2 (es)
EP (1) EP3570840B1 (es)
JP (3) JP7222895B2 (es)
KR (2) KR102610764B1 (es)
CN (4) CN117205313A (es)
AU (2) AU2018210397B2 (es)
BR (1) BR112019015011A2 (es)
CA (1) CA3049452A1 (es)
ES (1) ES3031468T3 (es)
IL (1) IL268138B (es)
MA (1) MA47310A (es)
MX (2) MX389966B (es)
UA (1) UA126970C2 (es)
WO (1) WO2018136796A1 (es)
ZA (1) ZA201904652B (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2735545C2 (ru) 2010-05-20 2020-11-03 Эррэй Биофарма Инк. Макроциклические соединения в качестве ингибиторов киназы trk
MA40386A (fr) 2014-07-31 2016-02-04 Exelixis Inc Procédé de préparation de cabozantinib marqué au fluor-18 et d'analogues de celui-ci
EP3442531A1 (en) 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
JP6888101B2 (ja) 2017-01-18 2021-06-16 アレイ バイオファーマ インコーポレイテッド ＲＥＴキナーゼ阻害剤としての置換ピラゾロ［１，５−ａ］ピラジン化合物
MX389966B (es) 2017-01-20 2025-03-20 Exelixis Inc Combinaciones de cabozantinib y atezolizumab para tratar cancer.
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
TWI876442B (zh) 2017-10-10 2025-03-11 美商絡速藥業公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之調配物
TWI791053B (zh) 2017-10-10 2023-02-01 美商亞雷生物製藥股份有限公司 6-(2-羥基-2-甲基丙氧基)-4-(6-(6-((6-甲氧基吡啶-3-基)甲基)-3,6-二氮雜雙環[3.1.1]庚-3-基)吡啶-3-基)吡唑并[1,5-a]吡啶-3-甲腈之結晶形式及其醫藥組合物
WO2019143977A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. Substituted pyrrolo[2,3-d]pyrimidines compounds as ret kinase inhibitors
JP6997876B2 (ja) 2018-01-18 2022-02-04 アレイ バイオファーマ インコーポレイテッド Ｒｅｔキナーゼ阻害剤としての置換ピラゾリル［４，３－ｃ］ピリジン化合物
WO2019143991A1 (en) 2018-01-18 2019-07-25 Array Biopharma Inc. SUBSTITUTED PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS AS RET KINASE INHIBITORS
MY210421A (en) 2018-01-26 2025-09-22 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
AU2019285066B2 (en) 2018-06-15 2024-06-13 Handa Pharmaceuticals, Inc. Kinase inhibitor salts and compositions thereof
WO2020051307A1 (en) * 2018-09-05 2020-03-12 Ventria Bioscience Inc. Formulations of immunoglobulin a
CA3111984A1 (en) 2018-09-10 2020-03-19 Array Biopharma Inc. Fused heterocyclic compounds as ret kinase inhibitors
TW202207940A (zh) * 2020-04-14 2022-03-01 美商健生生物科技公司 包含胺基嘧啶衍生物或其醫藥上可接受之鹽、水合物、或溶劑化物之用於經口投予之醫藥組成物
AU2021318134A1 (en) * 2020-07-31 2023-03-02 Exelixis, Inc. Combinations for the treatment of cancer
WO2022040555A2 (en) * 2020-08-21 2022-02-24 Exelixis, Inc. Method of treating cancer
KR20230158057A (ko) * 2021-03-19 2023-11-17 머크 샤프 앤드 돔 엘엘씨 항-ilt3 항체를 사용하여 암을 치료하는 방법
US11620580B2 (en) * 2021-04-01 2023-04-04 Banjo Health Inc. Methods and systems for probabilistic filtering of candidate intervention representations
EP4658271A1 (en) 2023-01-31 2025-12-10 Handa Oncology, LLC Improved cabozantinib compositions and methods of use

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2392565B1 (en) 2003-09-26 2014-03-19 Exelixis, Inc. c-Met modulators and methods of use
US20080200515A1 (en) 2006-12-29 2008-08-21 Tap Pharmaceutical Products Inc. Solid state forms of enantiopure ilaprazole
HUE065752T2 (hu) 2008-12-09 2024-06-28 Hoffmann La Roche Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére
RS52754B2 (sr) 2009-01-16 2022-08-31 Exelixis Inc Malat so n-(4- {[6,7-bis(metiloksi)hinolin-4-il]oksi}fenil-n'- (4-fluorofenil) ciklopropan-1,1-dikarboksamid-a, i njeni kristalni oblici za lečenje karcinoma
KR20180056807A (ko) 2010-07-16 2018-05-29 엑셀리시스, 인코포레이티드 C-met 조절제 약제학적 조성물
CN108472242A (zh) * 2013-04-04 2018-08-31 埃克塞里艾克西斯公司 治疗癌症的药物组合
EP3738952A1 (en) * 2014-02-14 2020-11-18 Exelixis, Inc. Crystalline solid forms of n-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use
EP3442531A1 (en) * 2016-04-15 2019-02-20 Exelixis, Inc. Method of treating renal cell carcinoma using n-(4-(6,7-dimethoxyquinolin-4-yloxy) phenyl)-n'-(4-fluoropheny)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
EP3445361A1 (en) * 2016-04-19 2019-02-27 Exelixis, Inc. Triple negative breast cancer treatment method
MX389966B (es) 2017-01-20 2025-03-20 Exelixis Inc Combinaciones de cabozantinib y atezolizumab para tratar cancer.

Also Published As

Publication number Publication date
US20190352403A1 (en) 2019-11-21
JP7222895B2 (ja) 2023-02-15
KR20230169458A (ko) 2023-12-15
WO2018136796A1 (en) 2018-07-26
NZ755494A (en) 2025-06-27
KR102610764B1 (ko) 2023-12-07
IL268138B (en) 2022-08-01
BR112019015011A2 (pt) 2020-04-28
MA47310A (fr) 2019-11-27
JP2022121594A (ja) 2022-08-19
JP2020514311A (ja) 2020-05-21
KR20190107103A (ko) 2019-09-18
IL268138A (en) 2019-09-26
ZA201904652B (en) 2024-11-27
AU2024203472A1 (en) 2024-06-13
EP3570840B1 (en) 2025-03-19
US11198731B2 (en) 2021-12-14
AU2018210397A1 (en) 2019-07-25
CN117205313A (zh) 2023-12-12
UA126970C2 (uk) 2023-03-01
MX2019008032A (es) 2019-12-16
AU2018210397B2 (en) 2024-02-29
CN117205312A (zh) 2023-12-12
US20220056138A1 (en) 2022-02-24
JP2024019720A (ja) 2024-02-09
CN117771363A (zh) 2024-03-29
CA3049452A1 (en) 2018-07-26
ES3031468T3 (en) 2025-07-09
EP3570840A1 (en) 2019-11-27
CN110352057A (zh) 2019-10-18
MX2022001718A (es) 2022-03-11

Similar Documents

Publication Publication Date Title
MX389966B (es) Combinaciones de cabozantinib y atezolizumab para tratar cancer.
BR112017023821A2 (pt) moduladores de k-ras
MX392368B (es) Composiciones y metodos para el tratamiento del cancer
ZA201905902B (en) 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer
MX2016007282A (es) Modulador del receptor de estrogenos para el tratamiento de cancer de mama positivo al receptor de estrogenos localmente avanzado o metastasico.
EA201990296A1 (ru) Антитела против siglec-7 для лечения рака
PT3337829T (pt) Método e composição para o tratamento do cancro, matando células cancerosas metastáticas e prevenindo as metástases do cancro usando anticorpos para produtos finais de glicação avançada (pga)
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112016024789A2 (pt) métodos de tratamento de câncer de mama em fase inicial com trastuzumabe-mcc-dm1 e pertuzumabe
NZ776616A (en) Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
EA201991818A1 (ru) Лечение рака
MX2019002925A (es) Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
EP3548088A4 (en) THERAPY FOR METASTATIC UROTHELIAL CANCER WITH THE ANTIBODY-DRUG CONJUGATE, SACITUZUMAB GOVITÉCAN (IMMU-132)
KR102004959B9 (ko) 전이성 난소암, 자궁내막암 또는 유방암의 예방 또는 치료용 조성물
IL281845A (en) Combination therapy for the treatment of cancer
IL282294A (en) Combinations for immune-modulation in cancer treatment
MX2019014298A (es) Formas de dosificacion liquida para tratar el cancer.
MX2018005867A (es) Integracion de las caracteristicas tumorales con el indice de cancer de mama.
LT3405213T (lt) Bakteriniai šešėliai, skirti panaudoti vėžio gydyme
SG11202010528XA (en) Combinations for treating cancer
IL281281A (en) Combination therapy for the treatment of prostate cancer
EA201691896A1 (ru) Соединения и способы их применения
IL282692A (en) Compounds derived from madrasin, a preparation and their uses for the treatment of cancer
DK3302551T3 (da) Fremgangsmåder til behandling af HER2-positiv tidligere ubehandlet metastatisk brystkræft
IL269769B (en) Compounds, composition and uses thereof for treating cancer